Abstract 157P
Background
Gastric cancer (GC) is among the most common malignancy worldwide. The UICC/AJCC TNM classification is the most commonly used classification system. For adequate N staging at least 15 lymph nodes should be retrieved. In some countries, this amount of lymph nodes is not met, which can lead to understaging. The phenomenon of stage migration is caused by an insufficient number of lymph nodes examined. In order to reduce stage migration, some investigators have proposed using the metastatic lymph node ratio (LNR), namely the ratio between positive lymph nodes compared with the total number of lymph nodes examined, as a new prognostic indicator for gastric cancer.
Methods
Total 116 patients who underwent upfront D2 gastrectomy between 2012 to 2017 were included. LNR has classified into 4 groups: LNR0; 0, LNR1; >0-0.13; LNR2; 0.14-0.40 and LNR3; 0.41-1. We have used Kaplan-Meier method to calculate survival rates and log rank test to compare survival curves between groups.
Results
Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years. Most common mode of presentation was pain abdomen (53.8%). Most common location of tumor was distal part (81%). Most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. 54 patients received adjuvant chemotherapy while 32 patients adjuvant chemoradiation. At a median followup of 14 months (range, 2–78 months), overall 5-year survival was 23.75%. (Median survival: 24 months). The 5-year survival for Stages I–III was 100%, 26.25%, and 11.25%, respectively (P < 0.001). In the univariate analysis; sex (p < 0.05), tumor grade (p < 0.001), T stage (p < 0.001), N stage (p < 0.001), TNM stage (p < 0.001), and LNR (p < 0.001) were statistically significant. The multivariate analysis showed that tumor grade, T stage, N stage, TNM stage and LNR still had statistical significance. In subgroup analysis of patients with less than 15 obtained lymph nodes, LNR was still a significant predictor of survival.
Conclusions
LNR can estimate prognosis of patients who undergo D2 gastrectomy, regardless of the number of lymph nodes examined. Thus LNR may become a new indicator to evaluate prognosis after D2 gastrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract